Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF for chronic hepatitis B with chronic kidney disease
ChiCTR2100049713Phase 4Not yet recruiting
- Sponsor
- Ningbo No. 2 Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Ningbo No. 2 Hospital. Primary endpoints: Routine blood test, Urinalysis and 10 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2100049713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049713.